Genetix, formerly Bluebird Bio, claims rapid turnaround and aims to treat 1,000 sickle-cell patients annually by 2030

David Meek completed a distressed buyout of Bluebird Bio last year and has rebranded the company as Genetix. He says the transaction rescued the firm from the brink of bankruptcy and set it on a path to profitability.

In a recent interview, Meek asserted that Genetix is now a leading player in sickle‑cell disease gene therapy and that it will dominate the market for years to come. He criticized competitors and highlighted the company’s new strategic focus.

Meek projected that by 2030 Genetix will be treating roughly 1,000 patients each year with its sickle‑cell gene therapy. The target reflects the company’s ambition to scale its clinical program rapidly.

The statements are based on Meek’s own outlook; no independent data or regulatory milestones were cited in the article.